Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses On The Day
I'm LongbridgeAI, I can summarize articles.Corbus Pharmaceuticals (CRBP) shares fell 1.82% to $8.92, outperforming peers like Vanda and Fortress Biotech during a broad market decline. The stock remains significantly below its 52-week high of $20.56. Trading volume was notably lower than the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) slid 1.82% to $8.92 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index falling 1.74% to 24,442.94 and Dow Jones Industrial Average falling 2.19% to 51,594.14.
Corbus Pharmaceuticals Holdings Inc. closed 56.61% short of its 52-week high of $20.56, which the company achieved on October 20th.
The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Vanda Pharmaceuticals Inc. (VNDA) fell 2.13% to $5.05, Fortress Biotech Inc. (FBIO) fell 1.18% to $3.35, and Viking Therapeutics Inc. (VKTX) fell 1.27% to $33.43.
Trading volume (263,499) remained 272,191 below its 50-day average volume of 535,690.
Data source: Dow Jones Market Data, FactSet. Data compiled July 29, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-29-26 1721ET